Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;21(6):594-608.
doi: 10.6004/jnccn.2023.0031.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

William J Gradishar  1 , Meena S Moran  2 , Jame Abraham  3 , Vandana Abramson  4 , Rebecca Aft  5 , Doreen Agnese  6 , Kimberly H Allison  7 , Bethany Anderson  8 , Harold J Burstein  9 , Helen Chew  10 , Chau Dang  11 , Anthony D Elias  12 , Sharon H Giordano  13 , Matthew P Goetz  14 , Lori J Goldstein  15 , Sara A Hurvitz  16 , Rachel C Jankowitz  17 , Sara H Javid  18 , Jairam Krishnamurthy  19 , A Marilyn Leitch  20 , Janice Lyons  3 , Joanne Mortimer  21 , Sameer A Patel  15 , Lori J Pierce  22 , Laura H Rosenberger  23 , Hope S Rugo  24 , Bryan Schneider  25 , Mary Lou Smith  26 , Hatem Soliman  27 , Erica M Stringer-Reasor  28 , Melinda L Telli  7 , Mei Wei  29 , Kari B Wisinski  8 , Jessica S Young  30 , Kay Yeung  31 , Mary A Dwyer  32 , Rashmi Kumar  32
Affiliations

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

William J Gradishar et al. J Natl Compr Canc Netw. 2023 Jun.

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates specific to systemic therapy recommendations for patients with stage IV (M1) disease.

PubMed Disclaimer

Similar articles

  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
    Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2021 May 1;19(5):484-493. doi: 10.6004/jnccn.2021.0023. J Natl Compr Canc Netw. 2021. PMID: 34794122
  • Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
    Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035. J Natl Compr Canc Netw. 2024. PMID: 39019058
  • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
    Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030. J Natl Compr Canc Netw. 2022. PMID: 35714673
  • Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
    Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Thompson JA, et al. J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020. J Natl Compr Canc Netw. 2022. PMID: 35390769 Review.
  • Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Gonzalez-Angulo AM, et al. Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources